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ABSTRACT 
Rationale, aims and objectives: To determine whether or not the label status of a medicine penetrates 
into the clinical reasoning of Australian medical practitioners, and to explore the possible reasons for 
our findings. 
Methods: Semi-structured interviews with 14 Australian physicians. 
Results: The interviews revealed three broad catalysts for off-label prescribing. The first of these was 
lack of awareness or understanding of the regulatory process in general and labels more specifically. The 
second was the perception that labels are not meaningful guides for clinical practice. The third was the 
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recognition of alternative mechanisms for ensuring safe, rational, and evidence-based prescribing 
occurs.   
Conclusion: This research suggests that Australian physicians do not consider whether or not a medicine 
is off-label to be a reliable measure of the appropriateness of their prescribing practices. Rather, 
legitimacy of prescribing practices is determined by the abilities, skills, and knowledge base of particular 
prescribers, by a culture that encourages and supports evidence-based practice, and safe prescribing. 
While labels are of minimal clinical significance, there are real conceptual, practical and moral problems 
associated with  conflating ‘good’ or ‘better’ practice with ‘on-label’ practice, and ‘bad’ or ‘worse’ 
practice with off-label prescribing as often occurs. To ascribe greater meaning to the term ‘off-label’ 
than is warranted can have the unintended consequence of casting suspicion upon, and making it more 
difficult for physicians to provide, appropriate clinical care. We conclude that labelling can, in some 
cases, provide assurances to both clinicians and patients that their medications have been 
demonstrated to be safe and effective, but that clinicians should be able to continue to prescribe 
responsibly off-label without having any stigma attached to their practice. 
Challenges to the validity of using medicine to categorise clinical behaviour:  an empirical and normative 
critique of ‘off-label’ prescribing 
 
INTRODUCTION 
Regulatory bodies, such as the US Food and Drug Administration (FDA), the European Medicines Agency 
(EMA), and Australia’s Therapeutic Goods Administration (TGA) are relied upon to assess medicines for 
their safety and efficacy on the basis of results from clinical trials in successively larger populations of 
patients [1]. As part of the approval process a ‘label’ is assigned to each medicine, which tells potential 
prescribers what disease/s it has been approved to treat, what age groups and doses are appropriate, 
what administration routes should be used, and how it should be used in pregnancy or other modifying 
conditions. 
Off-label prescribing refers to the clinical use of medicines in a manner that is different to that which is 
specified in the label. This may be because the medicine is being used  for a different disease or age 
group, at a different dose, and/or via a different route of administration. Pharmaceutical companies 
generally cannot promote their registered products for off-label uses – although recently the US federal 
court has ruled that the pharma company Amarin can promote its medicine Vascepa (icosapent ethyl) 
for ‘truthful’ off-label uses [2]. Doctors, on the other hand, are allowed to prescribe registered 
medicines in any way they see fit (bearing in mind that off-label prescribing may not be subsidised by 
public or private insurers).  
Off-label prescribing is very common. More than one fifth of all prescriptions in community practice are 
off-label [3], and in some specialties, medicines or conditions, off-label prescribing can constitute well 
over half of all prescriptions [3-8]. For instance, recombinant activated factor VII, indicated for patients 
suffering from specific forms of haemophilia, is used almost exclusively off-label within hospitals to 
control bleeding in non-haemophiliac patients, while cancer drugs such as gemcitabine and rituximab 
are used off-label the majority of the time [6, 7]. A number of Australian studies show that the 
proportion of patients that receive an off-label prescription seems to be higher than the number of 
drugs prescribed off-label (as many patients take multiple medicines of which only one may be off-label) 
[9, 10].  
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In recent years, off-label prescribing has become the focus of intense scrutiny following revelations that 
pharmaceutical companies have illegally promoted their medicines for off-label uses [11-15]. The 
concern about such off-label promotion has been that doctors’ prescribing practices have been 
influenced by industry promotion in a manner that is not in the best interests of patients [16-18].  
Those who criticize off-label prescribing (whether or not it is industry-driven) worry that off-label uses of 
medicines have not been sufficiently scrutinized by researchers and regulators, and therefore may be 
more harmful and/or less effective than expected [19]. They also note that, since we cannot be sure of 
the cost-effectiveness of these medicines, off-label prescribing could contribute to the wasteful use of 
scarce health care resources and lead to ‘label-creep’, whereby the clinical usage of a medicine expands,  
not as a result of evidence of its efficacy in clinical trials but rather as a result of advocacy by doctors, 
patients and pharmaceutical companies [20]. It has been argued that most off-label prescribing is 
supported by little or no scientific evidence [3]. More broadly, concerns have been expressed that off-
label prescribing bypasses and therefore undermines systems for regulating medicines [17, 21], and may 
also undermine clinical research as it reduces the incentive for pharmaceutical companies to conduct 
clinical trials and makes it more difficult to enrol patients into those trials that are conducted [22].  
Those who defend off-label prescribing note that if doctors were to strictly adhere to uses that have 
been approved by regulators, many people would never receive treatments that are likely to be 
beneficial. This is because the drug development and regulatory approval process is ultimately driven by 
claims that a drug sponsor—usually a pharmaceutical company—wishes to make [23], and these claims 
are often driven by profit motives rather than health care priorities [24]. This commercial imperative  
hinders the development of evidence for certain groups of patients, such as those suffering from rare 
diseases or so-called ‘diseases of poverty’, which affect mostly people in low- and middle-income 
countries.  
There are also other reasons that regulatory approval might never be sought for certain indications. For 
example, research might be thwarted by technical difficulties (such as the increasing complexity of trials 
of ‘targeted therapies’ and their ‘companion diagnostics’) or by ethical challenges (such as the perceived 
difficulties associated with including pregnant women and children in clinical trials). Furthermore, 
regulators do not actively seek out indications for which a drug will work, but simply evaluate the 
claim/s that a drug sponsor puts forward for assessment, meaning that drug labels can quickly become 
outdated and disconnected from the evolving evidence-base and from clinical needs [25].  
Worldwide, there has been relatively little empirical research focused on physicians’ understandings of, 
and reasons for, prescribing off-label. Those studies that have been conducted do provide some insights 
into the practice. One study of off-label paediatric prescribing amongst general practitioners in Scotland 
suggested that, while physicians appeared familiar with the concept of off-label prescribing, they 
wrongly believed it was not a common practice [26]. This appeared to be, in part, because the primary 
sources of medicines information they utilised were formularies, personal experience, and the 
experience of colleagues rather than regulatory labels. Another study utilised electronic health records 
available in Quebec, Canada, to investigate what factors influenced off-label prescribing in primary care, 
and discovered that older medicines and medicines with the fewest approved indications are most 
commonly used off-label [27]. It was also found that younger physicians were more likely to prescribe 
off-label without scientific support, while (unsurprisingly) the more physicians aligned themselves with 
evidence-based practice, the less likely they were to prescribe off-label.  
In a literature-based  case study we conducted exploring the emergence of the use of gabapentin use for 
neuropathic pain, we found that unmet clinical needs, prescribing precedents, and the perception that 
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gabapentin was a safe alternative to other treatment options were important drivers of off-label 
prescribing. In this and other case studies we have conducted into off-label prescribing [28-30] we found 
that, even when confronted with the same body of evidence, stakeholders may come to contrary views 
about the appropriateness of particular off-label prescribing practices – demonstrating that epistemic 
and ethical values heavily influence how evidence is interpreted. In this article, we build on our previous 
work by presenting the results of interviews with practicing physicians with a view to shedding further 
light on how off-label prescribing is conceptualised and practiced.  
METHOD 
The first author (NG) conducted semi-structured interviews with physicians practicing in a wide variety 
of fields including paediatrics (3), obstetrics and gynaecology (3), cardiology (2), general practice (2), 
mental health care (2),oncology (1), rheumatology (1), respiratory medicine (1) and pain management 
(1). Given that evidence suggests that physicians are often not aware of the fact they are prescribing off-
label [31] physicians were prompted to discuss not only off-label prescribing itself, but also the other 
ways in which they determine what is good or bad prescribing, the manner in which they deal with 
epistemic uncertainty, and how they balance risks and benefits. Questions were also asked about 
attitudes towards regulatory bodies more generally. Sampling was purposive--we were aiming for 
maximum variation to ensure that no major perspectives were overlooked.  In total fourteen physicians 
were interviewed, representing 9 specialties. 
The aggregate duration for all interviews was approximately 12.5 hours, with the average interview 
duration being approximately 54 minutes (interview durations ranged from 19 min through to 1hr 28 
min). Interviews were recorded and transcribed verbatim. Transcriptions were analysed using Morse’s 
outline of the cognitive basis of qualitative research [32], and Charmaz’s outline of data analysis in 
grounded theory [33]. Interviews were coded paragraph by paragraph, and a coding tree was generated 
(using XMind 6) from the themes to allow for higher-level categorization and conceptualization. Half of 
the interviews were double-coded by IK, ML and/or WL to ensure the validity of emerging themes, 
categories and concepts. Thematic saturation (the point at which no new themes were emerging) was 
reached after approximately 10 interviews. Ethics approval for this research was granted by the 
University of New South Wales Human Research Ethics Committee (Reference number: 2014-7-20) on 
19 May 2014. 
RESULTS 
The interviews revealed three broad catalysts for off-label prescribing. The first of these was lack of 
awareness or understanding of the regulatory process in general and labels more specifically. The 
second was the perception that labels are not meaningful guides for clinical practice. The third was the 
recognition of informal mechanisms for ensuring that prescribing is rational and responsible.   
Lack of awareness and understanding of labels and the regulatory system 
The interviews demonstrated enormous variation in the degree of understandingthat physicians had 
about off-label prescribing. While many of the physicians interviewed acknowledged that off-label 
prescribing was important to their practice, many had only a superficial understanding of its implications 
and meaning.  There appeared to be a general lack of awareness and understanding of the medicines 
governance processes. One experienced physician noted that she had only become aware of the phrase 
‘off-label prescribing’ in response to media attention focused on off-label promotion and regulatory 
failures, and admitted to having been relatively ignorant of the regulator’s role in medicines governance 
for most of her career: 
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“Things like the TGA [Australia’s medicines regulator] didn’t seem to have any meaning 
to me until … latter years in my career and … as governments become more involved in 
medicine we’ve seen … the TGA get mentioned a lot more and … the varieties of media 
that we have now enable us to hear a lot more about it.  I mean this concept of off label 
prescribing I’d never – to me, that’s a relatively recent thing.” 
Another senior physician expressed the belief that if medicines were available to clinicians, whether or 
not they were ‘on-label’ was essentially irrelevant. This physician believed that mere fact that a 
medicine had received marketing approval for any indication was evidence of its potential general 
utility: 
“…the mere fact that they’re available suggests that somebody, or the regulatory 
authorities, think that they’re not unreasonable to use… The reality is that people don’t 
look up [information to see whether a drug is on or off-label] – they know it’s available 
and they prescribe it, and I think it’s not that easy to look up every single drug to see, 
and I don’t think anyone really looks at it in that respect; if it’s available, it’s available…” 
To the extent that physicians were aware of the technical meaning of off-label prescribing, this 
awareness seemed to stem primraily from the fact that labels often determine which medicines will, and 
will not be formally subsidised by public and private insurers. For instance, one participant complained 
about how the privatization of their institution had meant that many patients who would have been 
provided subsidized off-label treatments in the past through their public hospital now had to pay for 
these medicines themselves or forgo treatment: 
“…that institution there, where I've been for the last [number of decades], used to 
provide drug committee permission to use the [off-label medicine] – that's being 
tightened up on.  So more and more patients are either being told, “Well, it's up to you if 
you can pay for it and if you can't, you can't have the drug.” ” 
One possible reason for many physicians’ lack of awareness and understanding of off-label prescribing 
related to the way they had learned to prescribe and utilise information. In this regard, it was 
noteworthy that none  of the participants in our study mentioned regulatory labels, or their 
accompanying product information, when they described their learning process. Instead, learning was 
described as occurring through ‘on-the-job’ immersion. Copying superiors and learning from what they 
did was particularly important in shaping prescribing habits. Specific activities, such as transcribing 
prescriptions onto medication charts as a junior physician, and being prepared to justify prescribing 
decisions to one’s superiors, were also important means of learning about prescribing.  
Lack of awareness of drug labels also seemed to stem from the rapid growth in online resources and 
computerised prescribing systems. As one physician stated in discussion about how they would 
approach prescribing unfamiliar medicines:  
“… it’s a very different world these days ...  The computer just spits up, you know, is the 
patient pregnant?  You are prescribing something that’s a category X drug, make sure 
the patient is not pregnant.  Um, there is a clinical indication it’s high risk, it’s low risk, 
it’s moderate risk – and it tells you basically what it is that you need to watch out for.  So 
it’s very, you know, it’s very helpful.  And previously you had to remember that all going 
back to the source and look through.  It didn’t give you the kind of detail that most 
computer programs do these days.  Which is … hugely helpful.” 
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The regulatory system is not percieved to be clinically focused and may impinge on practice 
Physicians’ lack of interest in using drug labels to guide their practice appeared to reflect, in part, their 
attitudes towards the regulator and the entire regulatory system. First, they did not believe that 
medicines regulation was of direct relevance to clinical practice. This perceived disconnect between the 
role of the regulator and the needs of physicians stemmed  in part from recognition of the fact that the 
evidence used in the regulation of medicines does not reflect the entire evidence base. In this regard, a 
number of participants noted that the regualtory system neglects entire areas of clinical practice and 
that, therefore, if the evidence exists for a particular use of a medicine, but this is not an approved use, 
then the problem lies with the drug development and regulatory system: 
“... in my field there’s a lot of stuff that’s off label and it’s not off label because it’s 
experimental, it’s off label because the pharmaceutical company doesn’t want to go 
through the time and expense of having it approved by the regulator in this country for 
that indication… If the scientific evidence exists that the drug is effective and safe, then it 
should be regulated for, you know, those indications in this country.” 
Several participants also pointed to the somewhat arbitrary nature of the regulatory system, noting 
differences in the approval of drugs internationally, different uses of medicines in the public or private 
health sector, and the imprecise characterisation of disease:  
“I mean, diseases, after all, especially chronic diseases, are really very woolly categories, 
very woolly categories… So I think the onus does fall ultimately on the prescriber to be 
able to rationally justify why that drug was prescribed.”  
Beyond simply finding medicines regulation to be arbitrary and/or of not direct clinical relevance, many 
participants suggested that the regulatory process in general, and use of labels in particular, could 
actually work against good clinical practice.  
For example, it was noted that regulators can be passive about what drugs are labelled and for what 
purposes. One physician, who had experience working in both government and the pharmaceutical 
industry, took this further, arguing that existing regulatory processes are replete with conflicts of 
interest and consequently place too much emphasis on the demands of industry. In his words: 
“I think the TGA [Australia’s medicines regulator] is useless.  I think it's conflicted in the 
way it’s structured.  It gets its funding and its very existence is dependent upon the 
medical device manufacturers and pharmaceutical manufacturers that it’s meant to be 
regulating so I think in its current format, it is completely dysfunctional… they're weak 
and wishy-washy with controlling things from the manufacturers – yeah, their control is 
weak over manufacturers and they don't wield a big stick because they're dependent on 
them for their funding.” 
This physician also believed that TGA processes for evaluating medicines were therefore not necessarily 
better than less formal peer driven processes (to be discussed further below).  
It was also suggested that there is a disjunction between regulatory approvals (and associated legal 
determinations of good practice) and what actually constitutes good clinical practice, and that concerns 
about the legalities of off-label prescribing could lead to poor clinical practice. For instance one 
physician was concerned about legal liability: 
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“So that’s another reason where I find the whole TGA [Australia’s medicines regulator] 
process unhelpful because, you know, stuff that I’m happy scientifically sound 
prescribing is, yeah, you know, a lawyer can go well that was a flake [since it is not 
officially on-label]...” 
Another interviewee noted how the link between labelling and funding could generate burdens for 
clinicians—particularly those working in the private sector, where funded indications are limited to 
those provided by the national insurer. This interviewee complained about how he had to spend more 
time engaging with pharmaceutical companies to seek subsidised or free access to off-label uses of 
medicines for their patients: 
“The other thing, of course, which is also incredibly tedious and wasteful of time, is 
actually - I mean I really don't like doing it, actually contacting the industry and seeing 
if they will let – you know, provide something with an incentive scheme…” 
Informal mechanisms of risk management are just as important as formal mechanisms of control 
Who is prescribing is just as important as what is being prescribed 
A key theme that arose in the interviews is that the appropriateness of a prescribing decision depends 
not only on the medicine used, but also upon who is using the medicine. Freedom to prescribe was 
therefore associated not with what a regulator did, or did not, endorse, but rather with one’s status 
within one’s field. This view was  most explicitly expressed by one interviewee who made it clear that 
while evidence-based practiced (including, but not only consideration of labels) was important for junior 
practitioners, and non-specialists, experts should have freedom to prescribe according to their 
judgement, even if this means prescribing contrary to the information held by ‘the drug authorities’: 
“I think there are situations where prescriptions that may be appropriate for a sub 
specialist who's considered an expert in his field to take what he perceives as a very 
small risk, um, but would not be comfortable with, um, general practitioners 
prescribing… I would certainly, ah, be very keen for experts to be given a relatively free 
hand by the drug authorities”. 
Indeed it seems that to some participants, the very point of being an expert is to have lee-way both to 
prescribe in areas of epistemic uncertainty and to make use of whatever evidence may be available, 
whether or not this evidence has been formally assessed by regulatory authorities. As one physician 
noted:  
“Oh, routine practice, absolutely, you know.  So every – every day, every decision that I 
make is usually based around what is the available evidence.  Because there are 
definitely, you know, in my field, there are things where we are absolutely crystal clear 
on issues – not very many of those –but there are, you know, certainly really strong 
good evidence base, lots of randomised trials, fantastic work, crystal clear.  Most of it is 
kind of less clear, a little bit grey… it’s the grey zone that’s always the problem, isn’t it?” 
Expertise was seen to be associated with a special kind of knowledge and intimacy with particular 
clinical areas, as well as with medicines recognised as ‘tools of the trade’. Some physicians noted that 
through prescribing the same medicines over extended periods of time, they became intimately familiar 
with how particular medicines worked, to the point physicians may even prefer specific brands of the 
same medicine over others due to subtle differences they have noticed.  
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“So, I think, not everything on evidence-based is correct, and I think sometimes one 
needs one’s own judgment … a very important thing is experience, and if a large 
pharmaceutical trial shows that there’s no increased incidence of a certain adverse 
effect, and you commonly get this adverse effect, and it gets better when you stop the 
drug, well then, you have to be guided by your own experience.”   
Indeed, for experts to be too risk averse, and restrict their prescribing to the claims on the regulatory 
label was seen by some to undermine good prescribing.  As one physician noted: 
“I see a lot of what I would call … poor prescribing from … fear and hypersensitivity …” 
and continues by stating “Um, and just because it’s not [on-label]… doesn’t mean that I 
as an individual clinician am, you know, not going to prescribe that drug just ‘cause the 
TGA hasn’t listed it.” 
While expertise was seen by physicians to provide greater leeway in prescribing decisions, the 
application of expertise was more legitimate in the context of prescribing drugs already known to be 
relatively safe. As might be expected, even experts were hesitant to utilise medicines that were 
dangerous or had unknown safety profiles in order to gain a benefit for their patient.  
Rational and responsible prescribing can be, and is, encouraged in other ways 
Even expert physicians acknowledged that some epistemic controls over their prescribing were 
important, and that they needed, at times to be  ‘seen’ to be practicing evidence-based medicine in 
order to develop good habits in less experienced junior doctors. Even here, however, the idea of 
epistemic control, and the practice of evidence-based medicine were understood in ethical, political and 
cultural, rather than formal, regulatory terms. One physician distinguished clearly between interventions 
they believed would work, and what they were permitted to use within a particular practice culture: 
“…… I cannot take my personal opinion and apply it on the public without any further 
studies… it can be the truth.  But, then, at the same time, it's not supported in western 
medicine, you cannot really practice medicine unless it's supported by evidence.” 
This physician also noted the erosion of trust in physicians as influencing how medicine is practiced, a 
point picked up on by others as reflected by the need to maintain the integrity of medicine by avoiding 
prescribing in ways that may further undermine trust.  
The existence of oversight by peers was also perceived to be an important mechanism of control. For 
instance one physician shared an instance of how she they had been challenged to justify why she were 
prescribing  a drug in an off-label manner: 
“… somebody wrapping my knuckles one day, over me using a certain drug because I 
actually wanted to use it for its beneficial effect and for its side effects at the same 
time… I think that physician thought I was going to do something harmful by exploiting 
the side effects, but backed off with that concern when I justified my position.”   
It was also noted that complex decisions were rarely made alone, but only after consultation with peers. 
One physician noted that as a junior doctor, you would only independently prescribe ‘very obvious 
drugs’. Hence solidarity was an important mechanism for ensuring legitimacy of prescribing practices. As 
one interviewee noted: 
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“I mean, I guess what a lot of people don’t realise in the public is, at a major teaching 
hospital, complex cases are discussed, you know.  Every unit would have a multi-
disciplinary meeting once a week where complex patients are discussed.  And it may 
involve different specialties even, as well.  And that’s where those sort of decisions are 
made, where you’ve got someone who’s sick and doesn’t fit into the trial, and this hasn’t 
worked, they are discussed.”   
Some interviewees also described that pharmacists would sometimes vet their prescriptions, and while 
one interviewee was frustrated by the fact a pharmacist might challenge a decision to use a medicine in 
a manner contradictory to official information, others recognised the value in having their decisions 
scrutinised by a third party: 
“I sometimes get a phone call from a pharmacist.  And I’m delighted when they do do 
that 'cause they’re just checking whether I really meant that … [However] I think you 
cannot rely on a pharmacist interpreting what they’re seeing ...” 
Clinical guidelines and medicines compendia were also considered to be important sources of direction 
and information, while formularies were identified as an important determinant of practice as they set 
limits around what medicines physicians (or their patients) may have access to. While these sources of 
information are obviously derived, to some extent, from regulatory guidance, none of our participants 
explicitly viewed them this way. Rather, they were seen as part of the process by which one becomes 
enculturated to be a good prescriber. 
“And dosing, again you didn’t really learn that in medical school.  I found when I went 
through that it was when I was an intern, um, that I learned what were the most 
common medications that were used, and the doses …  So we had a formulary, um, in 
hospital, um, so we would prescribe in that way.”   
Discussion 
Study limitations 
This study has a number of limitations. All participants were recruited in Australia (although a number 
had also practiced overseas), and therefore the views of these physicians cannot necessarily be 
extrapolated to physicians practicing in other countries. Most of the physicians interviewed for this 
project were specialists, and specialists are more likely to prescribe off-label than non-specialists. 
Therefore these results are not representative of all prescribers. Furthermore the interviewees were 
recruited from diverse specialties, and therefore the results cannot be said to be representative of any 
single specialty. As only 14 interviewees were recruited, these results provide only indicative 
understandings of, and attitudes towards, off-label prescribing.  
The clinical significance of a medicine being ‘off-label’ 
The data from this study suggest that Australian physicians justified off-label prescribing by way of three 
positive and three negative criteria. On the positive side, they argued first that drugs agreed to be ‘safe’ 
can be used for conditions not included in the original approval if there is some link – either theoretical 
or practical – to suggest a possible beneficial effect.  
Second, they argued that clinical—particularly specialist—expertise and a sense of responsibility 
towards patients provides assurance of the safest possible use of off-label drugs. The physicians 
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interviewed all felt strongly that the commitment involved in specialist practice ensured their capacity to 
pay conscientious and skilled attention to unwanted side-effects, and to harness clinically useful side-
effects of ‘off-label’ medicines. 
Third, the physicians declared their respect for evidence-based medicine, but argued that effectiveness 
was the practical criterion that underpinned their prescribing choices, rather than the efficacy that 
determines the authorisation of a drug and its labelling. They thus committed themselves to a social 
epistemology that depended less on ‘gold standard’ trials, and more on evidence generated at ‘lower’ 
levels of the EBM hierarchy. 
On the negative side, most of the physicians expressed a relative ignorance or indifference to the 
clinical, ethical or legal implications of labelling. There was some concern about possible legal effects of 
off-label prescribing, but generally off-label prescribing was simply a part of rational and responsible 
prescribing, requiring clinical skill, careful monitoring and remaining informed of accumulating 
information. The precise role of the label was not clear to them. 
Second, some of the physicians went further in arguing that labelling and the authorisation processes 
involved, was irrelevant to the actual practice of clinical care, and could in fact be harmful. In the 
Australian context, lack of regulatory authorisation of a drug for a particular purpose might mean a lack 
of government subsidy, which imposes significant costs on patients or hospitals. Authorisation and 
labelling thus impose restrictions on the abilities of physicians to prescribe, and on access to 
medications for patients. 
In addition to restricting what physicians could prescribe, the need to obtain authorisation to prescribe 
unregistered (and therefore unfunded) medicines created what we refer to as ‘hierarchical dissonance’. 
By this we mean the apparent disconnect between bureaucratic management and clinical practice. 
Decisions made around committee tables were seen by practitioners to be decisions made beyond the 
realities of practice.  
Our interviews with Australian physicians suggest that whether a medicine is on, or off-label, does not 
determine, in their minds, whether a particular  prescribing practice is legitimate or not. Rather, 
legitimacy is determined by abilities, skills, and knowledge base of particular prescribers, and by a 
culture that encourages and supports rational and responsible practice, and safe prescribing.  
This is consistent with the findings of a series of literature-based case studies we conducted into the 
published discourses surrounding the off-label use of recombinant activated factor VII for uncontrolled 
bleeding, misoprostol for post-partum haemorrhage, and gabapentin for neuropathic pain, where the 
fact a medicine was off-label was almost never offered as a reason for not using these medicines [28-
30]. Indeed, we could only find one instance where the fact that misoprostol was off-label for post-
partum haemorrhage in most countries was raised as a point of concern, as it may increase the potential 
for dangerous use of incorrect doses due to insufficient official guidance on the most effective and 
safest dosage regimen [34]. In the case of gabapentin for neuropathic pain, even intense controversy 
regarding off-label promotion of the medicine did not seem to override the clinical warrants for utilising 
the medicine off-label, namely the view that it was a safer and a more convenient alternative than 
medicines already being used for neuropathic pain. In the case of recombinant activated factor VII for 
management of uncontrolled bleeding, the label was only invoked when some physicians were critical of 
the FDA’s contradictory position of being reluctant to support research into acutely injured patients, 
while at the same time not accepting reduced blood loss as a surrogate end-point in clinical trials 
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investigating rFVIIa’s efficacy in trauma patients (the FDA demanded evidence of improved survival and 
hence rejected the results of the Phase III trials) [35].  
It could be argued that the knowledge (or lack thereof) and attitudes of fourteen—or even a much 
larger number—of Australian physicians only describes a deficiency that needs to be rectified with 
further information and education about the importance of regulatory labels and the dangers of off-
label prescribing. We would, however, disagree with this view because the label not only had  very 
limited clinical significance in this study, but also has a general tendency to inadvertently categorise 
particular prescribing practices as ‘good’ or ‘bad’. This attitude is highlighted in an invited commentary 
to JAMA Internal Medicine in which Good and Chester interpret one study to imply that off-label 
prescribing is, in most cases, not in the best interest of patients’: 
“Although in some clinical circumstances the off-label prescribing is clearly within the 
best interests of the patient, Eguale and colleagues have documented that this scenario 
occurs infrequently.” [[36], p. 64] 
We believe this claim is unwarranted on the basis of our study and our previous literature-based 
research. Internationally, as well as in Australia it must be recognised that while a drug being off-label 
may imply many things, it does not determine anything specifically. Off-label prescribing may be 
perceived as non evidence-based (which seems to be the main contention of critics), but may also be 
based on strong evidence. Off-label prescribing may be construed as poor practice, but it may also be 
considered best practice. Off-label prescribing may waste limited health care resources, but may also be 
the most cost-effective use of resources. Off-label prescribing may represent straying from established 
treatment regimens, or it may represent judicious personalisation to address the needs of patients with 
complex needs. Off-label prescribing may expose some patients to greater harms, but may also provide 
benefits that would otherwise have been denied to these patients.  
The clinical meaningfulness of the drug label is further called into question by the fact (also recognised 
by clinicians) that regulators in different countries may come to different conclusions about the 
scientifically valid uses of the same medicines, using the same evidence to make these determinations. 
For instance, gabapentin was approved for use of neuropathic pain in Australia in 2000, whereas the 
United States refused to make it on-label for this general indication due to a percieved paucity of 
scientific evidence, and therefore only listed it for one form of neuropathic pain - postherpetic neuralgia 
[30]. This inconsistency between the US and Australian label persists to this day.  
Further blurring the clinical significance of the on-label/off-label dichtomy is the fact that respected 
organisations such as the Cochrane Collaboration and the National Institute for Health and Care 
Excellence routinely provide evidence summaries for off-label uses of medicines to support physicians 
[37]. The World Health Organisation also recognises that off-label uses of medicines have a place on the 
Essential Medicines List, a case in point being misoprostol for post-partum haemorrhage [38]. In 
addition, while clinical practice guidelines and hospital  formulary writers most certainly consider labels, 
these forms of guidance are not restricted to on-label uses of medicines. It is noteworthy that clinical 
guidelines are defined by the Institute of Medicine as ‘recommendations intended to optimize patient 
care’ based on the assessment of ‘the benefits and harms of alternative care options’, neither function 
of which the label fulfills on its own [39]. 
What all this suggests is that the term ‘off-label’ is sufficiently vague to be almost meaningless in clinical 
terms. However, this is not the only problem. As our participants noted, in Australia the labelling status 
of a drug can also, in theory, expose doctors to greater liability, and in Europe at least, prescribing an 
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off-label alternative to an on-label drug just because it is more cost-effective may be illegal [40]. Despite 
the ambiguity around what ‘off-label’ means, negative connotations are inevitably implied by the term, 
and this is sustained by blanket demands from some stakeholders for greater consent requirements, and 
more intensive patient education requirements when utilising medicines in this way [41, 42].  It is also 
worth noting that there is no agreement between stakeholders internationally on a positive definition of 
off-label prescribing as pointed out by Neubert and colleagues, although they did manage to get 85% 
(n=34) of participants to agree on a definition [43]. Therefore the only thing the label can be said to 
definitely mean is that the regulator has endorsed a particular therapeutic claim based on studies of 
safety and efficacy, and as our results suggest, this is not necessarily meaningful to physicians.  
The need to remove the stigma attached to off-label prescribing 
This raises the obvious question: if regulatory labels cannot—and should not—be used to distinguish 
between ‘good’ and ‘bad’ (or even ‘better’ and ‘worse’) clinical practice, what role do labels have 
beyond simply being a formal record of evidence that a regulatory body has assessed? What the label 
does provide for physicians is perhaps the best systematic assessment of a medicine’s approved  use at 
the time of market introduction. Therefore the label assists with the safe introduction of a new 
technology into the health system when there may be little other evidence and experience with it. It 
also ensures there is a minimum level of evidence available about a new medicine for the medical 
community to work with – particularly relating to safety and efficacy. Indeed a medicine’s first 
registration is perhaps the only point at which society can demand a specific standard of evidence from 
pharmaceutical companies. We contend this socio-political function of setting the tone around the 
amount and quality of evidence society expects, in general terms rather than in the details, is perhaps 
the most important role of the regulatory process. However, this does not mean that the regulator has a 
special epistemic or ethical warrant to determine what is, or is not, an appropriate use of a medicine in 
any particular clinical case – and as our results suggest, this is definitely not the view of the physicians 
we interviewed. In practice, we think this means that while labelling can, in some cases, provide 
assurances to both clinicians and patients that their medications have been demonstrated to be safe 
and efficacious in clinical trials, clinicians should be able to continue to prescribe responsibly off-label 
without having any stigma attached to their practice. 
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